UNC569  纯度: 98.64%

UNC569 是一种有效、可逆、ATP 竞争性且具有口服活性的 Mer 激酶抑制剂,IC50 为 2.9 nM,Ki 为 4.3 nM。UNC569 还抑制 Axl 和 Tyro3,IC50 分别为 37 nM 和 48 nM。UNC569 可用于急性淋巴细胞白血病 (ALL) 和非典型畸胎瘤/横纹肌瘤的研究。


UNC569 Chemical Structure

CAS No. : 1350547-65-7

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
5 mg ¥1100 In-stock
10 mg ¥1800 In-stock
25 mg ¥4000 In-stock
50 mg ¥6500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

UNC569 相关产品


  • Bioactive Compound Library Plus
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Anti-Cancer Compound Library
  • Orally Active Compound Library
  • Anti-Blood Cancer Compound Library
  • Targeted Diversity Library


UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC50 of 2.9 nM and a Ki of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC50s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research[1][2]

IC50 & Target

IC50: 2.9 nM (Mer), 37 nM (Axl), 48 nM (Tyro3)[1] Ki: 4.3 nM (Mer)[1]

(In Vitro)

UNC569 (24 hours) induces apoptosis in ALL cell lines, and increases the levels of cleaved Caspase 3 and cleaved PARP[2].
UNC569 (1 µM; 1.5 hours) treatment effectively inhibit the activation of Mer and downstream signaling, including the PI3K/AKT and MAPK/ERK pathways[2].
UNC569 (1 hour) inhibits Mer phosphorylation levels with IC50 values of 141 nM and 193 nM in human B-ALL (acute lymphoblastic leukemia) 697 and Jurkat cell lines, respectively[1][2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[2]

Cell Line: 697 and Jurkat cells
Concentration: 0.4 µM, 0.8 µM, 1 µM, 1.2 µM, 1.4 µM, 1.6 µM, 1.8 µM, 2 µM
Incubation Time: 24 hours
Result: Induced apoptosis in ALL cell lines.

Western Blot Analysis[2]

Cell Line: 697 and Jurkat cells
Concentration: 1 µM
Incubation Time: 1.5 hours
Result: Inhibited Mer activation and downstream signaling through ERK1/2 and AKT.

(In Vivo)

The in vivo pharmacokinetic properties of UNC569 (3 mg/kg) are also assessed in mice via both intravenous (IV) and oral (PO) administration. UNC569 has low systemic clearance (19.5 mL/min/kg), high volume of distribution (Vss of 5.83 L/kg), and good oral bioavailability (57%)[1].
Leukemic zebrafish are treated continuously for 2 weeks by immersion in 4 µM UNC569. the result shows that UNC569 induces more than 50% reduction in tumor burden compared with vehicle- and mock-treated fish[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.








Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
In Vitro: 

DMSO : 31.25 mg/mL (78.81 mM; Need ultrasonic)

浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5221 mL 12.6103 mL 25.2207 mL
5 mM 0.5044 mL 2.5221 mL 5.0441 mL
10 mM 0.2522 mL 1.2610 mL 2.5221 mL


储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (6.31 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.31 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
  • [1]. Jing Liu, et al. Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. ACS Med Chem Lett. 2012 Feb 9;3(2):129-134.

    [2]. Sandra Christoph, et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77.